News

Cutiss: Series B Financing Round successfully secured with CHF 18.7 Mio.

Zurich, Switzerland, June 4 2020 – CUTISS AG, an innovative Swiss Life Science Company aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced it has successfully secured its series B financing round. Funds raised so far...

read more

MEMO THERAPEUTICS AG IDENTIFIES POTENT SARS-COV-2-NEUTRALIZING ANTIBODIES FROM THE BLOOD OF RECOVERED COVID-19 PATIENTS

Schlieren, Switzerland – 4 June 2020 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and immune repertoire analysis, today announces that it has identified several SARS-CoV-2-specific virus-neutralizing antibodies with the potential for development as a COVID-19 immunotherapy. MTx’s DROPZYLLA® platform isolated ultra-rare and highly potent...

read more

Analytical performance of Proclarix® verified

Zurich-Schlieren, Switzerland, May 19, 2020. Proteomedix, the Swiss cancer diagnostics company announces today the publication of the analytical performance results of Proclarix, Proteomedix lead product for improved prostate cancer diagnostics in the peer-reviewed journal PLOS ONE. The report published today highlights the analytical performance of the two CE-IVD assays that measure...

read more

Molecular Partners to Present Preclinical Data from MP0317, AMG 506 / MP0310 and Peptide-MHC Programs at AACR Annual Meeting

Zurich-Schlieren, Switzerland, May 15, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced the presentation of preclinical data from three of the company’s programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting II, June...

read more